AIM ImmunoTech
About: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Employees: 28
0
Funds holding %
of 6,794 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0.85% more ownership
Funds ownership: 14.93% [Q2] → 15.77% (+0.85%) [Q3]
8% less funds holding
Funds holding: 36 [Q2] → 33 (-3) [Q3]
24% less capital invested
Capital invested by funds: $3.18M [Q2] → $2.41M (-$773K) [Q3]
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$1
383%
upside
Avg. target
$1
383%
upside
High target
$1
383%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Jason McCarthy 39% 1-year accuracy 9 / 23 met price target | 383%upside $1 | Buy Maintained | 22 Oct 2024 |
Financial journalist opinion
Based on 11 articles about AIM published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here
Neutral
GlobeNewsWire
2 days ago
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
ISS Notes Need for Significant Board Change at AIM Due to Clinical Failure and Lack of Transparency According to ISS – “ There is no question that for shareholders to have any hope of not losing 100 percent of their investment, significant change is needed ” 1 ISS Recommends to Vote on the Kellner Group's GOLD Card for Ted Kellner and Paul Sweeney ISS Recommends Against Votes for Thomas Equels and Stewart Appelrouth ISS Further States – “ Equels appears to be the most directly responsible for the company's failings ” 2 Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders Kellner Group has Clear Plan to Stabilize AIM and Create Value NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W.
Neutral
Business Wire
3 days ago
ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended that shareholders vote “FOR” Company nominees Nancy K. Bryan and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), presently scheduled for December 17, 2024. In reaching its recommendation against giving the activist investors' (the “Ac.
Neutral
Business Wire
6 days ago
AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation highlighting why shareholders should NOT elect the four director candidates nominated by a group of activist investors (collectively, the “Activist Group”) as part of their multi-year attempt to take over AIM's Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), presently scheduled for December 17, 2024. View the ful.
Neutral
GlobeNewsWire
6 days ago
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
Kellner Group Has Financial Resources AIM Needs Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders AIM Cash Conservation Plan is Too Little Too Late, Exposes Desperate Financial Condition AIM Stock Price has Declined 99+% Frantic AIM Board Doubles Down on Attempts to Deceive Stockholders NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W.
Neutral
Business Wire
1 week ago
AIM ImmunoTech Refutes Activist Group's False and Misleading Claims
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement refuting the false and misleading claims recently made by a group of activist investors (collectively, the “Activist Group”) relating to their multi-year attempt to take over AIM's Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”), presently scheduled for December 17, 2024. Since 2016, the Board and managem.
Neutral
Business Wire
1 week ago
AIM ImmunoTech Announces Cash Conservation Plan
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Compensation Committee of the Company's Board of Directors (the “Board”) has established a cash conservation plan (the “Cash Conservation Plan”). The Cash Conservation Plan is a key part of the Board and management team's efforts to bolster the Company's ability to maintain its momentum in achieving key clinical milestones in areas with critical unmet needs – which we believe.
Neutral
Business Wire
1 week ago
AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation in connection with its upcoming 2024 Annual Meeting of Stockholders the (“Annual Meeting”), presently scheduled for December 17, 2024. Highlights of the presentation include the following: AIM is executing on its strategy to create long-term value for patients and shareholders by driving clinical development programs in areas with critical unmet needs, especially in the hi.
Neutral
GlobeNewsWire
2 weeks ago
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer Center's Phase 1 study evaluating AIM ImmunoTech's drug Ampligen® (also known as rintatolimod) as a component of a chemokine-modulating (CKM) regimen in early-stage triple-negative breast cancer (TNBC). Results of the study were reported in The Journal for ImmunoTherapy of Cancer .
Neutral
Seeking Alpha
3 weeks ago
AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript
AIM ImmunoTech Inc. (NYSE:AIM ) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Scientific Officer Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Hello, and welcome to the AIM ImmunoTech Third Quarter 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Charts implemented using Lightweight Charts™